期刊文献+

老年男性血清抵抗素水平与外周动脉硬化闭塞症的关系 被引量:3

Relation between serum resistin level and peripheral artery occlusive disease in elderly males
下载PDF
导出
摘要 目的探讨老年男性血清抵抗素水平与外周动脉硬化闭塞症(PAOD)的关系。方法选择843例老年男性患者,分为PAOD组165例和非PAOD组678例。检测血清抵抗素及C反应蛋白水平,进行相关分析。结果PAOD组血清抵抗素水平明显高于非PAOD组[(7.26±2.94)ng/L vs(6.49±3.09)ng/L,P<0.05]。血清抵抗素水平与C反应蛋白和HDL-C独立相关(β=0.058,β=-0.810,P<0.05)。抵抗素是PAOD的独立危险因素(P=0.004)。结论老年男性PAOD患者血清抵抗素水平升高,血清抵抗素水平可能是PAOD发病的预测因素。 Abstratct:Objective To study the relation between serum resistin level and peripherial arterial occlusive disease(PAOD)in elderly males.Methods Eight hundred and forty-three elderly male patients were divided into PAOD group(n=165)and non-PAOD group(n=678).Their serum levels of resistin and CRP were mesured and analyzed by correlation analysis.Results The serum resistin level was significantly higher in PAOD group than in non-PAOD group(7.26±2.94ng/Lvs6.49±3.09ng/L,P〈0.05)and independlty related with the serum CRP and HDL-C level(P〈0.05).The incidence of PAOD increased with the serum resistin level,indicating that resistin was an independent risk factor for PAOD.Conclusion Serum resistin level is significantly higher in elderly male PAOD patients and may be a predictive factor for PAOD.
出处 《中华老年心脑血管病杂志》 CAS 北大核心 2014年第8期795-797,共3页 Chinese Journal of Geriatric Heart,Brain and Vessel Diseases
关键词 抵抗素 外周血管疾病 动脉粥样硬化 C反应蛋白质 胆固醇 HDL resistin peripheral vascular diseases atherosclerosis C-reactive protein cholesterol HDL
  • 相关文献

参考文献2

二级参考文献18

  • 1Newman AB, Siscovick DS, Manolio TA, et al. Ankle-arm index as a marker of atherosclerosis in the cardiovascular health study. Circulation, 1993,88:837-845.
  • 2Murabito JM, Evaans JC, Nieto K, et al. Prevalence and clinical correlates of peripherial arterialk disease in Framingham. Am Heart J, 2002,143:96:1-5.
  • 3Meijer WT, Hoes AW, Rutgers D, et al. Peripheral arterial disease in the elderly: the Rotterdam Study. Arterioscler Thromb Vasc Biol ,1998,18:185-192.
  • 4Hirsch AT, Criqui MH, Treat JD, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA ,2001,286:1317-1324.
  • 5Osmundson PJ, O′Fallon WM, Clements IP, et al. Reproducibility of noninvasive tests of peripheral occlusive arterial disease. J Vasc Surg,1985,2:678-683.
  • 6Fowkes FGR. The measurement of atherosclerotic peripheral arterial disease in epidemiological surveys. Int J Epidemiol ,1988,17:248-254.
  • 7Cleeman JL. Executive summary of thr third report of the national cholesterol education program(NCEP) expert panel on detection,evaluation, and treatment of high blood cholesterol in adults (adult treatment panel Ⅲ. JAMA ,2001,285:2486-2489.
  • 8Violi F, Criqui M, Longoni A, et al. Relation between risk factors and cardiovascular complications in patients with peripheral vascular disease. Results from the A.D.E.P. study. Atherosclerosis ,1996,120:25-35.
  • 9Ness J, Aronnow WS. Prevalence of coexistence of coronary artery disease, ischemic stroke and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatric practice. J Am Geriatr Soc ,1999,47:1255-1256.
  • 10Dagennais GR, Maurice S, Robitaille NM, et al. Intermittent claudication in Quebec men from 1877-1986: the Quebec cardiovascular study. Clin Invest Med ,1991,14:93-100.

共引文献37

同被引文献22

  • 1张庆林,肖凤君,毕建进,刘红军,段海峰,劳妙芬,吴祖泽.重组质粒pUDKH的质量分析[J].生物技术通讯,2006,17(5):733-736. 被引量:2
  • 2Nakamura T,Sakai K, Nakamura T, et al. Hepatocyte growth factor twenty years on.. much more than a growth factor. J Gastroenterol Hepatol, 2011,26 : 188 -202.
  • 3Sanada F,Taniyama Y, Azuma J, et al. Therapeutic angiogen esis by gene therapy for critical limb ischemia choice of bio logical agent. Immunot Endocr Metab Agents Med Chem 2014,14,32- 39.
  • 4Sanada F,Taniyama Y,Kanhara "Y',et al. Gene therapy in pe- ripheral artery disease. Expert Opin Biol Ther, 2015,15 : 381- 39O.
  • 5ldo A, Moriuchi A, Numata M, et al. Safety and pharmacoki- netics o{ recombinant human hepatocyte growth factor (rh- HGF) in patients with fulminant hepatitis a phase; I / g clin- ical trial, following preelinical studies to ensure safety. J Transl Med, 2011,9 - 55.
  • 6Ginn SL, Alexander IE, Edelstein ML, et al. Gene therapy clinical trials worldwide to 2012-an update. J Gene Med, 2013,1565-77.
  • 7Zhang Q, Bi J, Xiao F, et ai. Production of plasmid DNA enco- ding human hepatocyte growth factor for gene therapy. Bio- technol Appl Biochem, 2008,49 : 11 -16.
  • 8Chunsheng H,Qinglin Z,Yuxin Let al. A continuous cell al- kaline lysis, neutralization, and clarification, combination process for production of plasmid pUDK-HGF. Biotechnol Appl Biochem, 2011,58 : 162-165.
  • 9Cui S,Guo L, Li X, et al. Clinical safety and preliminary effi- cacy of plasmid pUDK-HGF expressing human hepatocyte growth factor (HGF) in patients with critical limb ischemia. Eur J Vasc Endovasc Surg,2015,50:494- 501.
  • 10Fowkes FG, Rudan D, Rudan I, et al. Comparison of global es- timates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet, 2013,382 : 1329-1340.

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部